Evidence Table N3: DISCRETE outcomes for class OTHER.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	N.01.02			**Gugulipid**	**Tetracycline**	
325 ↑ Parallel Sev N=20		**Severity change (michaelsson)**	Mid (12)	Excellent 3 Good 7 Poor 0	Excellent 2 Good 6 Poor 2	**0.05**
		Post-therapy relapse	Long (96	Relapse 2 No relapse 8	Relapse 4 No relapse 6	
	N.01.03			**Isolutrol**	**Benzoyl peroxide**	
94 Parallel Mild/mod N=70		**Burning**	Mid (12)	Present 1 Absent 34	Present 12 Absent 23	**0.05**
		Dryness	Mid (12)	Present 11 Absent 24	Present 29 Absent 6	**0.05**
		Erythema	Mid (12)	Present 3 Absent 32	Present 17 Absent 18	**0.05**
		Pruritis	Mid (12)	Present 5 Absent 30	Present 15 Absent 20	**0.05**
		Scaling	Mid (12)	Present 3 Absent 32	Present 25 Absent 10	**0.005**
	N.01.04			**Ocimum basilicum**	**Tetracycline**	
17 ↓ Parallel N=51		**Severity change (grade)**	Mid (8)	100% reduction 0 >50% reduction 20 <50% reduction 3 No reduction 0	100% reduction 0 >50% reduction 14 <50% reduction 3 No reduction 6	
				Increase 2	Increase 3	
	N.01.05			**Tea tree oil**	**Benzoyl peroxide**	
18 ↑ Parallel Mod N=124		**Unwanted effects**	Mid (12)	Present 27 Absent 31	Present 50 Absent 13	**0.001**
	N.02.01			**Clobetasol**	**Vehicle**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
175 ↑ Parallel split face Mod N=11		**Severity change**	Short (3)	Overall reduction in active lesions 6 Overall increase in active lesions 2 Little change 3	Overall reduction in active lesions 1 Overall increase in active lesions 0 Little change 10	**NS**
	N.02.04			**Neomycin + methyl prednisolone**	**Vehicle**	
228 Parallel N=776		**Overall change/physician**	Short (5)	Improved 355 Not improved 69	Improved 76 Not improved 75	**0.001**
	N.02.05			**Methyl prednisolone + neomycin + sulfur**	**Vehicle**	
102 ↑ Parallel N=134		**Overall change**		Excellent 29 Good 22 Same 13 Worse 2	Excellent 16 Good 20 Same 27 Worse 5	**0.02**
	N.02.06			**Neomycin + methyl prednisolone**	**Aluminum chlorhydroxide + sulfur**	
228 Parallel N=776		**Overall change/physician**	Short (5)	Improved 355 Not improved 69	Improved 142 Not improved 59	**0.001**
	N.03.01			**Gamma-globulin**	**Placebo**	
189 Parallel Mod/sev N=40		**Overall change/physician**	Long (80	None 5 Fair 4 Good 7 Very good 8	None 1 Fair 3 Good 8 Very good 4	
		Side effects	Long (80	Pain 2	Pain 0	
	N.03.03			**Staphylococcal toxoid**	**Vehicle**	
222 ↑ Parallel Mild/mod/sev N=66		**Adverse reation**	Short (1)	Colds with fever 10 Axillary adenitis 2	Colds with fever 2 Axillary adenitis 0	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
222 ↑ Parallel Mild/mod/sev N=66		**Overall change/patient**	Mid (10)	Cure complete 0 Great improvement 5 Partial improvement 16 No improvement 12	Cure complete 0 Great improvement 0 Partial improvement 5 No improvement 25	
		Overall change/physician [mild]	Mid (10)	Worse 1 Improved 9 Not improved 5	Worse 2 Improved 3 Not improved 4	
		Overall change/physician [moderate]	Mid (10)	Improved 9 Not improved 6	Improved 10 Not improved 12	
		Overall change/physician [severe]	Mid (10)	Improved 5 Not improved 0	Improved 2 Not improved 1	
		Overall change/patient	Long (24	Cure complete 0 Great improvement 8 Partial improvement 15 No improvement 11	Cure complete 0 Great improvement 2 Partial improvement 13 No improvement 16	
		Overall change/physician [mild]	Long (24	Worse 0 Improved 7 No 7	Worse 1 Improved 1 No 6	
		Overall change/physician [moderate]	Long (24	Improved 11 Not improvement 4	Improvement 4 Not improvement 18	
		Overall change/physician [severe]	Long (24	Improved 3 Not improved 2	Improved 0 Not improved 3	
	N.04.01			**Chloramphenicol + hydrocortisone**	**Vehicle**	
297 Parallel Mild/mod N=32		**Overall change/patient**	Short (4)	Definitely better 12 Possibly better 2 No change 0 Worse 0	Definitely better 6 Possibly better 5 No change 3 Worse 0	**0.05**
		Overall change/physician	Short (4)	Missing 1 Definitely better 12 Possibly better 1 No change 1 Worse 0	Missing 1 Definitely better 6 Possibly better 4 No change 4 Worse 0	
				Missing 1	Missing 1	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
297 Parallel Mild/mod N=32		**Severity (burton)**	Short (4)	0 0 1 8 2 5 3 1	0 0 1 1 2 12 3 1	**0.05**
		Overall change/patient	Mid (8)	No record 1 Definitely better 10 Possibly better 2 No change 1 Worse 0	No record 1 Definitely better 4 Possibly better 1 No change 7 Worse 2	**0.05**
		Overall change/physician	Mid (8)	Missing 2 Definitely better 10 Possibly better 2 No change 1 Worse 0	Missing 1 Definitely better 4 Possibly better 2 No change 5 Worse 3	
		Severity (burton)	Mid (8)	Missing 2 0 0 1 12 2 1 3 0	Missing 1 0 0 1 6 2 4 3 4	
		Withdrawals due to side effects	Mid (8)	No record 2 Withdraw 0 Did not withdraw 15	No record 1 Withdraw 5 Did not withdraw 10	**0.014**
	N.04.02			**Hydrocortisone + buttoxethyl nicotinate + chloramp**	**Vehicle**	
224 ↑ Cross-over Mild/mod/sev N=120		**Side effects**	Mid (10)	Itchiness/ dryness 5	Itchiness/ dryness 3	
	N.04.03			**Chloramphenicol + hydrocortisone + sulfur**	**Chloramphenicol + sulfur**	
142 Parallel Mild/mod N=50		**Overall change/patient**	Short (4)	Improved 22 Not improved or worse 0	Improved 21 Not improved or worse 1	**NS**

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
142 Parallel Mild/mod N=50		**Overall change/physician**	Short (4)	Improved 22 Not improved or worse 0	Improved 22 Not improved or worse 0	**NS**
		Overall change/patient	Mid (12)	Improved 13 Not improved or worse 9	Improved 14 Not improved or worse 8	**NS**
		Overall change/physician	Mid (12)	Improved 11 Not improved or worse 11	Improved 15 Not improved or worse 7	**NS**
	N.04.04			**Chloramphenicol + hydrocortisone + sulfur**	**Hydrocortisone + sulfur**	
115 ↑ Parallel N=37		**Overall change/patient**	Short (4)	Improved 14 Same 2 Worse 0 No data 0	Improved 12 Same 8 Worse 1 No data 0	
		Overall change/physician	Short (4)	Improved 14 Same 2 Worse 0 No data 0	Improved 15 Same 5 Worse 1 No data 0	
		Local reactions	Mid (12)	Irritant and poor cosmesis 0	Irritant and poor cosmesis 1	
		Overall change/patient	Mid (12)	Improved 8 Same 3 Worse 2 No data 3	Improved 7 Same 6 Worse 3 No data 5	
		Overall change/physician	Mid (12)	Improved 9 Same 2 Worse 2 No data 3	Improved 7 Same 6 Worse 4 No data 4	
	N.04.05			**Chloramphenicol + hydrocortisone + sulfur**	**Benzoyl peroxide**	
75 ↑ Parallel Mod N=48		**Erythema**	Mid (12)	Necessitating treatment reduction 5	Necessitating treatment reduction 2	
		Scaling	Mid (12)	Necessitating treatment reduction 4	Necessitating treatment reduction 6	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	N.05.01			**Grenz rays**	**Sham rays**	
138 ↑ Parallel split face N=40		**Post-therapy overall state/observer**	Mid (7)	Better 10 Same 19 Worse 4	Better 4 Same 19 Worse 10	
		Post-therapy overall state/observer	Mid (9)	Better 14 Same 14 Side 1	Better 1 Same 14 Side 14	
139 ↑ Parallel split face N=33		**Post-therapy overall state/observer**	Mid (7)	Better 9 Same 12 Worse 2	Better 2 Same 12 Worse 9	
		Post-therapy overall state/observer	Mid (9)	Better 12 Same 14 Worse 2	Better 2 Same 14 Worse 12	
		Post-therapy overall state/observer	Long (16	Better 1 Same 8 Worse 1	Better 1 Same 8 Worse 1	
179 Parallel split face N=40		**Improvement**	Short (5.	Worse 1 Unchanged 15 Improved 10 Greatly improved 12	Worse 2 Unchanged 16 Improved 12 Greatly improved 8	
180 Parallel split face N=42		**Severity change (group %)**	Short (4)	Worse 3 Unchanged 9 Improved 16 Greatly improved 18	Worse 3 Unchanged 13 Improved 18 Greatly improved 8	
	N.05.02			**Comedone extraction (cheeks/forehead)**	**Untreated**	
216 ↑ Parallel split face N=12		**Inflammatory change**	Long (24	Better 8 Worse 4	Better 4 Worse 8	
	N.06.04			**Hydrochlorthiazide**	**Placebo**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
284 ↓ Parallel N=50		**Overall change**	Mid (8)	Usual 12 Less 4 Better 9	Usual 18 Less 0 Better 7	
	N.06.04			**Hydrochlorthiazide**	**Vehicle**	
178 ↓ Cross-over N=42		**Premenstrual overall change/patient [phase ii]**	Short (4)	Poor 11 Fair 3 Good 6 Excellent 1	Poor 6 Fair 4 Good 7 Excellent 4	
		Premenstrual overall change/physician [phase i]	Short (4)	Reduced 7 Not reduced 14	Reduced 12 Not reduced 9	
		Adverse reactions/No withdrawals	Mid (8)	Headache 20 Unresolved edema 3	Headache 15 Unresolved edema 6	
		Adverse reactions/Withdrawals	Mid (8)	Itching 1 Dizziness and heartburn 1 Nausea 1 Weakness 1	Itching 0 Dizziness and heartburn 0 Nausea 0 Weakness 0	
				Fainting/lethargy 0	Fainting/lethargy 1	
		Premenstrual change/patient [phase ii]	Mid (8)	Poor 5 Fair 10 Good 5 Excellent 1	Poor 10 Fair 5 Good 5 Excellent 3	
		Premenstrual overall change/physician [phase ii]	Mid (8)	Reduced 8 Not reduced 13	Reduced 8 Not reduced 13	
	N.06.05			**Tolbutamide**	**Vehicle**	
110 ↑ Parallel Mod/sev N=30		**Overall change/patient**	Mid (12)	Worse 0 Same 5 Improved 8	Worse 1 Same 6 Improved 10	
		Overall change/physician	Mid (12)	Worse 0 Same 6 Improved 7	Worse 0 Same 7 Improved 10	
		Severity/photo	Mid (12)	Worse 2 Same 6 Improved 5	Worse 2 Same 6 Improved 9	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
	N.07.02			**Zinc**	**Placebo**	
91 ↑ Parallel Mod N=66		**Nausea**		Nausea 3	Nausea 3	
		Severity/patient	Mid (8)	Improvement-none 12 Improvement-slight 11 Improvement-marked 9	Improvement-none 22 Improvement-slight 8 Improvement-marked 4	**0.002**
		Severity/photo	Mid (8)	Improvement-none 8 Improvement-slight 12 Improvement -marked 12	Improvement-none 26 Improvement-slight 5 Improvement-marked 3	**0.0001**
	N.07.02			**Zinc sulfate**	**Placebo**	
3 Parallel N=42		**Overall change/physician**	Mid (12)	Better 8 No change 3 Worse 6	Better 7 No change 6 Worse 5	
341 ↑ Parallel Mild/mod N=52		**GI distress**	Mid (12)	Nausea/vomiting (withdraw) 6 Nausea/vomiting (remained) 5 Diarrhea 3	Nausea/vomiting (withdraw) 0 Nausea/vomiting (remained) 1 Diarrhea 0	
	N.07.02			**Zinc sulfate**	**Vehicle**	
336 ↑ Parallel Mod N=56		**Oilness**	Short (6)	No change 12 Less oiliness/seborrhea 17	No change 27 Less oiliness/seborrhea 0	
		Severity change	Short (6)	Excellent 3 Moderate 10 Slight 1 Very slight 11	Excellent 12 Moderate 3 Slight 2 Very slight 10	
		Side effects	Short (6)	Aggravation 2 Nausea/withdraw 1 Nausea 3 None 25	Aggravation 2 Nausea/withdraw 0 Nausea 0 None 27	
342 ↑ Parallel Mod N=39		**Side effects**		Nausea/ vomiting (withdraw) 2 Nausea/ vomiting (no withdraw) 3	Nausea/ vomiting (withdraw) 0 Nausea/ vomiting (no withdraw) 0	
	N.07.02			**Zinc suphate**	**Placebo**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
163 Parallel Mod/sev N=112		**Withdrawal due to side effects**		Nausea & vomiting 1 Diarrhea 1 Fatigue & headache 0 Pruritis 1	Nausea & vomiting 2 Diarrhea 1 Fatigue & headache 1 Pruritis 0	**NS**
		Overall change/patient	Short (4)	Much improved 11 Improved 14 Somewhat improved 13 Unchanged 7	Much improved 8 Improved 5 Somewhat improved 15 Unchanged 9	**0**
		Overall change/physician	Short (4)	Worse 1 Much worse 0 Much improved 9 Improved 17 Somewhat improved 11 Unchanged 5	Worse 3 Much worse 0 Much improved 7 Improved 8 Somewhat improved 13 Unchanged 7	**NS**
		Overall change/patient	Mid (12)	Worse 3 Much worse 1 Much improved 23 Improved 13 Somewhat improved 7 Unchanged 4	Worse 5 Much worse 0 Much improved 14 Improved 8 Somewhat improved 12 Unchanged 7	**0.02**
		Overall change/physician	Mid (12)	Worse 1 Much worse 0 Much improved 20 Improved 18 Somewhat improved 2 Unchanged 6	Worse 2 Much worse 0 Much improved 13 Improved 10 Somewhat improved 8 Unchanged 8	**0.01**
		Side effects	Mid (12)	Worse 2 Much worse 0 Slight nausea initially 2 Vomiting 1 Gastric discomfort 1 Dryness of mouth 1	Worse 4 Much worse 0 Slight nausea initially 0 Vomiting 0 Gastric discomfort 0 Dryness of mouth 0	**NS**
				Slight gastric discomfort 0 Nausea 0	Slight gastric discomfort 1 Nausea 1	
	N.08.02			**Erythromycin + zinc**	**Erythromycin**	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method Info	Compar-ison	Discrete Outcome Name (Units) Definition/Comments	Follow-up (wks)	Treatment Attribute: Number of patient	Comparator Attribute: Number of patients	Between P-value
147 ↑ Parallel Mod N=122		**Local side effects**		Withdraw 2 Mild 11	Withdraw 2 Mild 6	
	N.08.03			**Erythromycin + zinc**	**Clindamycin phosphate**	
300 Parallel Mod N=103		**Cutaneous**		Burning/redness/withdraw 1 Irritation 0 Absent 47	Burning/redness/withdraw 0 Irritation 1 Absent 43	

TRIAL: ↑↓ -presence of positive or negative methodological features (see Summary Table). "Mild/mod," etc., -our assessment of entry severity of study patients. "P"- to parallel study, "S"-split face design. BETWEEN P-VALUE: comparison between Target and Comparator arms.